Clozaril® (clozapine) is indicated in the management of symptoms of treatment-resistant schizophrenia. In controlled clinical trials, clozapine was found to improve both positive and negative symptoms.1

Please consult the CLOZARIL® Product Monograph at for contraindications, warnings, precautions, adverse reactions, drug interactions (particularly CYP 450 isoenzymes inhibitors or inducers drugs), dosing, and conditions of clinical use. The Product Monograph is also available by calling 1-800-267-2726.

1. Clozaril® Product Monograph. HLS Therapeutics Inc., May 31, 2022.

For Canadian Residents Only | Français

Resources for Healthcare Professionals

The following resources provide information on CLOZARIL® and the CLOZARIL® Support and Assistance Network® (CSAN®).

Clozaril® Product

CLOZARIL® Healthcare Professional Brochure

Learn about treatment-resistant schizophrenia and about CLOZARIL® as an option in the management of symptoms of treatment-resistant schizophrenia

CSAN® Enrolment Form

Registration of CLOZARIL® patients, their current location, treating physician, testing laboratory and dispensing pharmacist in the CSAN® system is required. 1

Download the CSAN® form to enroll your patients.


Stay up to date with information on CSAN®, treatment-resistant schizophrenia, and CLOZARIL®.
Download the latest newsletter or subscribe to receive future issues.

You may update your information or unsubscribe to the CSANewsletter by contacting HLS Privacy Officer